CEL-SCI CORP. NEW DL-01
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more
Market Cap & Net Worth: CEL-SCI CORP. NEW DL-01 (LSRM)
CEL-SCI CORP. NEW DL-01 (F:LSRM) has a market capitalization of $548.63 Million (€534.48 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #25889 globally and #2826 in its home market, demonstrating a 2643.46% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CEL-SCI CORP. NEW DL-01's stock price €5.87 by its total outstanding shares 91037296 (91.04 Million).
CEL-SCI CORP. NEW DL-01 Market Cap History: 2015 to 2025
CEL-SCI CORP. NEW DL-01's market capitalization history from 2015 to 2025. Data shows growth from $31.77 Million to $548.63 Million (26.41% CAGR).
CEL-SCI CORP. NEW DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CEL-SCI CORP. NEW DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LSRM by Market Capitalization
Companies near CEL-SCI CORP. NEW DL-01 in the global market cap rankings as of March 19, 2026.
Key companies related to CEL-SCI CORP. NEW DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CEL-SCI CORP. NEW DL-01 Historical Marketcap From 2015 to 2025
Between 2015 and today, CEL-SCI CORP. NEW DL-01's market cap moved from $31.77 Million to $ 548.63 Million, with a yearly change of 26.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €548.63 Million | +1454.82% |
| 2024 | €35.29 Million | -85.25% |
| 2023 | €239.23 Million | +26.17% |
| 2022 | €189.60 Million | -70.34% |
| 2021 | €639.18 Million | -29.44% |
| 2020 | €905.88 Million | +27.55% |
| 2019 | €710.20 Million | +192.31% |
| 2018 | €242.96 Million | +71.28% |
| 2017 | €141.85 Million | +2100.00% |
| 2016 | €6.45 Million | -79.71% |
| 2015 | €31.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of CEL-SCI CORP. NEW DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $548.63 Million USD |
| MoneyControl | $548.63 Million USD |
| MarketWatch | $548.63 Million USD |
| marketcap.company | $548.63 Million USD |
| Reuters | $548.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.